Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies - Report - MDSpire

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • By

  • Jiashun Li

  • Ainikaer Abulaiti

  • Deyu Li

  • Yan Zhao

  • Paerhati Wahafu

  • Maerdan Maimaitiming

  • Shi Qiu

  • Yuxiang Zhang

  • Yaqin An

  • Wenxing Wang

  • Liangquan Shi

  • Maihemuti Yakufu

  • Li Shu

  • Guohua Li

  • Zhen Liu

  • June 22, 2026

  • 0 min

Share

Correction: Efficacy and Safety of CD3 Bispecific Antibodies in Myeloma

Background

CD3 bispecific antibodies targeting BCMA and GPRC5D are being studied in the treatment of relapsed/refractory multiple myeloma (RRMM). Understanding the funding and support behind these studies is essential for transparency in clinical research.

Data Highlights

No numerical or trial data is presented in the correction.

Key Findings

  • The correction clarifies the funding sources for the systematic review and meta-analysis.
  • The original article's scientific conclusions remain unchanged despite the correction.
  • BCMA-targeted therapies have been a focus of recent clinical trials and real-world studies.
  • Regulatory approvals for BCMA-directed therapies have increased, highlighting their importance in RRMM treatment.
  • Ongoing research continues to evaluate the safety and efficacy of these therapies in diverse patient populations.

Clinical Implications

Clinicians should be aware of the funding sources of clinical studies to assess potential biases.

Conclusion

The correction addresses an error in the funding statement of the published research.

Related Resources & Content

  1. Li J et al., Front. Immunol., 2026 -- Assessment of the Efficacy and Safety of CD3 Bispecific Antibodies Targeting BCMA or GPRC5D
  2. Blood Cancer Journal — Clinical Characteristics Linked to Suboptimal Response and Early Recurrence After BCMA-Targeted Treatments in Multiple Myeloma
  3. Blood Cancer Journal — Pre-treatment Debulking Approach Before Administration of Anti-BCMA/CD3 Bispecific Antibodies in Patients with Extramedullary Disease and/or High Tumor Burden Relapsed or Refractory Multiple Myeloma: A Retrospective Analysis
  4. Blood Cancer Journal — Analysis of Peripheral Blood Immune Cell Characteristics and Their Response to BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma
  5. The ASCO Post — In Case You Missed It: Additional Studies of Interest From ASH 2024
  6. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma
  7. EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
  8. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
  9. Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study - Schinke - 2025 - Cancer - Wiley Online Library
  10. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results - PMC
  11. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma | FDA
  12. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma - PMC
  13. NCCN guidelines focus on treatment options for patients with multiple myeloma - Nierengarten - 2025 - Cancer - Wiley Online Library
  14. Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis | Annals of Hematology | Springer Nature Link

Original Source(s)

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies

  • by Jiashun Li, Ainikaer Abulaiti, Deyu Li, Yan Zhao, Paerhati Wahafu, Maerdan Maimaitiming, Shi Qiu, Yuxiang Zhang, Yaqin An, Wenxing Wang, Liangquan Shi, Maihemuti Yakufu, Li Shu, Guohua Li, Zhen Liu

  • June 22, 2026

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
An ASCO preview: What to watch for at cancer research’s big meeting

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma